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Abstract: A convenient five step synthesis of (S)-homolysine, incorporating a key olefin cross-
metathesis step in the chain extension methodology, has been developed, together with a six step 
related synthesis of a new homologue of arginine, (S)-bishomoarginine. 
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Introduction 
Cationic amino acids, such as arginine and lysine, are important constituents of biologically active 
peptides,
1,2
 and play a significant role in the binding of peptide substrates and their molecular targets. 
Homologues of these cationic amino acids are also valuable tools in the preparation of peptidic enzyme 
inhibitors and, in particular, for probing enzyme active site pockets in ligand based drug design.
3
 For 
example, (S)-homolysine 1 (shown as the di-HCl salt), a nonproteinogenic amino acid, has been used as 
a lysine replacement residue in vasopressin
4
 and in cyclic enkephalin analogues
5
 as well as in the design 
of renin inhibitors.
6
 Homoarginine is found in several proteins, including some within the brain,
7
 and it 
has also been shown to inhibit arginine kinases.
8
 In this context, extended homologues such as (S)-
bishomoarginine 2 (shown as the di-HCl salt) would also be of considerable interest. However, no 
method for the preparation of 2 has been reported. Previous syntheses of its potential precursor 
homolysine 1, produce either the racemic form
9
 or an enantiomerically enriched form by excessive 
multistep methods from a chiral cyclic amino acid template,
10,11
 or by constructing a chiral aldehyde 
template from serine and applying Wittig methodology to incorporate the desired sidechain.
12
 
Homolysine 1 was then finally produced by deprotection protocols in the synthesis. Facile access to 
both 1 and 2 in high enantiomeric purity would provide increased opportunities for the incorporation of 
 
2 
these unnatural amino acids into drug discovery processes, including combinatorially-based and 
rational drug design programs. 
 
Results and Discussion 
We report here an efficient synthesis of both (S)-homolysine 1 and (S)-bishomoarginine 2. Our strategy 
(Scheme 1) incorporated the stereochemical element using commercially available (S)-allylglycine, 
thus avoiding the use of chiral templates. The reliable olefin cross-metathesis reaction
13
 provided the 
necessary chain elongation and established guanidation methodology
14
 was then applied for the required 
primary amine to guanidine functional group transformation. This strategy of amino acid chain 
elongation via olefin cross-metathesis could potentially be used to prepare a variety of unnatural amino 
acids and amino acid homologues rapidly, with the advantage of incorporating the C2-chiral 
stereocentre from the outset. 
 
Therefore, the protected amine 5 was prepared
15
 by treating the bromobutene 3 with di-tert-
butyliminodicarboxylate and cesium carbonate affording the di-Boc-homoallylic amine 4, which was 
then selectively deprotected with two equivalents of TFA in dilute CH
2
Cl
2
 to give the N-Boc-allylamine 
5 in an overall yield of 89% (Scheme 1).  
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Scheme 1: Synthesis of (S)-Lysine and (S)-Arginine Homologues 
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Reaction of 5 with half an equivalent of the protected allylglycine derivative 6
16
 and Grubbs’ ruthenium 
catalyst I in an analogous manner to reported cross-metatheses of allylglycines
17,18
 afforded 7 in 
moderate yield (69%) as a mixture of E/Z stereoisomers. It is interesting to note that a homo-dimer of 
the protected allylglycine 6 was not observed as sometimes reported for similar cross-metathesis 
conditions with allylglycine derivatives.
19
 Both the E and Z isomers were evident in the 
1
H NMR 
spectrum from the doubling up of most signals, however the exact ratio could not be determined due to 
overlapping signals. Preparation of bishomoarginine 2 required removal of the acid labile N-Boc 
protecting group of 7 by treatment with TFA. Subsequent exposure to N-triflyl-N,N-di-tert-
butoxycarbonyl-protected guanidine (Aldrich Chemical Co.) and triethylamine then yielded the 
protected arginine analogue 8 in 93% yield. The alkene group and benzylcarbamate protecting group of 
7 and 8 were then removed in one step by hydrogenation over Pd/C to yield the free amino esters 9 and 
10, in 90% and quantitative yields, respectively. Exposure of the amino ester derivatives 9 and 10 to 
10M HCl for 48 h resulted in the free amino acids 1 and 2, as their corresponding dihydrochloride salts, 
in quantitative yield. 
 
The specific rotation observed for 1 ([α]
D
22
 +10.9 (c. 0.1 in 2N HCl)), was in general accordance with 
the reported literature values for the enantiomeric hydrochlorides ([α]
D
23
 -10.6 (c. 1, 1N HCl) (R)-
isomer
12
 and [α]
D
23
 +14.4 (c. 0.5, in 1 N HCl) (S)-isomer
11
), while the previously unreported 2 had an 
[α]
D
22
 of –23.3 (c. 0.03 in 2M HCl). Further evidence for the enantiomeric purity of 1 was forthcoming 
from the peptide coupling reaction of its immediate precursor, 9, with the known
20
 chiral protected 
tyrosine derivative O-allyl-N-acetyl-(S)-tyrosine 11
21
 (Scheme 2). The dipeptide derivative 12 from this 
coupling showed a diagnostic sharp single peak in the 
1
H NMR spectrum at δ  3.69, integrating for 3 
protons. Our experience with these types of dipeptides has shown us that this methyl ester peak is 
indicative in delineating the presence of diastereomers, and in the case of 12, the dr was calculated to 
be >96%.
22 
Consistent with this NMR analysis, the chiral GC analysis (Chirasil L-Val) of the N-
pentafluoropropionyl, isopropyl esters of 1 and 2 showed a single peak whereas the same derivatives of 
racemic lysine and arginine showed two well resolved peaks (see Experimental section for details).  
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Scheme 2: Synthesis of the diastereomeric dipeptide 12. 
 
Conclusion 
The presented methodology provides a rapid and convenient synthesis of (S)-homolysine 1 in five steps 
in 55% overall yield which is an improvement over the previously reported procedure (9 steps, 22 % 
overall yield) of Beaulieu et al.,
12
 and that of Dong
11
 (5 steps, 51 % overall yield). Bishomoarginine 2 
was prepared in six steps, in 57% overall yield. The flexibility of the methodology also allows, in 
principle, for the synthesis of the corresponding (R)-amino acids, via the commercially available (R)-
allylglycine. 
 
Experimental 
All NMR spectra were determined in CDCl
3
 solution at 300 MHz (
1
H NMR) or 75MHz (
13
C NMR) 
unless otherwise stated. All compounds were determined to be >95% pure by 
1
H NMR spectroscopy. 
Enantiomeric purities of amino acids was made on their N-pentafluoropropionyl isopropyl esters by gas 
chromatography on a fused silica capillary column coated with the stationary phase Chirasil L-Val.
23 
Derivatisation of the amino acids was performed according to published procedures.
23 
 Derivatisation: 1 
mg of the amino acids were transferred to 3 mL Pierce reaction-vials using methanol and brought to 
dryness under a stream of dry nitrogen. Esterification of the amino acids was undertaken by adding 250 
µL of 3.5 N isopropanol/HCl and heating for 1 hour at 110
o
C. The samples were then allowed to cool to 
ambient temperature and were subsequently dried under a stream of dry nitrogen. Samples were then 
acylated with 250 µL of CH
2
Cl
2
 and 50 µL of pentafluoropropionic acid anhydride (PFPA) and heated 
 
6 
at 110
o
C for 15 minutes. After cooling, samples were dried completely under a stream of nitrogen. Gas 
Chromatography: Analysis of the N-pentafluoropropionyl-amino acid isopropyl esters were undertaken 
using a Varian model 3700 gas chromatograph with a flame ionization detector and a coiled, fused 
silica capillary column (25 m length) coated with the stationary phase Chirasil-L-Val. The temperature 
program consisted of a single ramp set at the following conditions: (1) initial temperature 50
o
C for 2 
minutes; (2) ramp at 4
o
C/minute to a ceiling at 200
o
C and (3) a plateau at 200
o
C for 10 minutes. High 
purity helium was used as a carrier gas. An authentic sample of D,L-lysine showed two peaks at 
retention times of 32.19 and 32.33 minutes, while L-homolysine 1 showed a single peak at retention 
time of 33.57 minutes. An authentic sample of D,L-arginine showed two peaks at retention times of 
32.12 and 32.26 minutes, while L-bishomoarginine 2 showed a single peak at retention time of 29.30 
minutes.
 
 
Di-tert-Butyl N-3-butenyliminodicarboxylate (4) 
To a solution of di-tert-butyl iminodicarboxylate (868 mg, 4 mmol), cesium carbonate (2.61 g, 8 
mmol), and lithium iodide (28 mg, 0.2 mmol) in 2-butanone (20 mL) was added 4-bromo-1-butene 3 
(812 mg, 6 mmol) and the mixture was heated at reflux for 48 h. The reaction was allowed to cool, 
quenched with brine (40 mL) and then extracted with diethyl ether (3 x 20 mL). The combined organic 
fractions were washed with brine (30 mL), dried (MgSO
4
) and concentrated to yield the title compound 
4 (1.01 g, 3.7 mmol, 93%) as a light brown oil.
 
υ
max
(neat) 2974 (s), 1735 (s), 1697 (s), 1129 (s) cm
-1
. 
1
H 
NMR: δ 5.84-5.70 (m, 1H, H3); 5.10-4.99 (m, 2H, H4); 3.62 (dd, J = 6.0, 8.7 Hz, 2H, H1); 2.36-2.29 
(m, 2H, H2); 1.51 (s, 18H, 6 x CH
3
). 
13
C NMR: δ 152.5, (CO); 135.0, (C3); 116.7, (C4); 82.0, (2 x 
C(CH
3
)
3
); 45.6, (C1); 33.5, (C2); 28.0, (6 x CH
3
). MS (ES, +ve) m/z 272 (40%) [MH
+
], 294 (30%) 
[MNa
+
], 310 (55%) [MK
+
]. HRMS (ES) calcd for C
14
H
26
NO
4
 272.1862, found 272.1848. 
 
tert-Butyl N-3-butenylcarbamate (5)
 
To a solution of 4 (708 mg, 2.60 mmol) in CH
2
Cl
2
 (21 mL) was added TFA (593 mg, 5.20 mmol) and 
the mixture was allowed to stir at RT for 5 min before being quenched with 2M NaOH (25 mL) and 
extracted with CH
2
Cl
2
 (3 x 20 mL). The combined organic fractions were dried (MgSO
4
) and 
concentrated to yield the title compound 5
15
 (429 mg, 2.50 mmol, 96%) as a light brown oil. υ
max
(neat) 
2979 (s), 1799 (m), 1732 (s), 1697 (s), 1392 (m), 1367 (s), 1130 (s) cm
-1
.
 1
H NMR: δ 5.83-5.69 (m, 1H, 
H3); 5.13-5.05 (m, 2H, H4); 4.59 (bs, 1H, NH); 3.20 (dd, J = 6.3, 12.6 Hz, 2H, H1); 2.24 (dd, J = 6.9, 
12.6 Hz, 2H, H2); 1.44 (s, 9H, 3 x CH
3
). 
13
C NMR: δ 155.9, (CO); 135.3, (C3); 117.0, (C4); 82.0, 
(C(CH
3
)
3
); 39.6, (C1); 34.2, (C2); 28.4, (3 x CH
3
). MS (ES, +ve) m/z 116 (100%). 
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Methyl (2S)-2-benzyloxycarboxamido-4-pentenoate (6)
16 
To a solution of methyl (2S)-2-amino-4-propenoate hydrochloride
24
 (422 mg, 2.56 mmol) and NaHCO
3
 
(645 mg, 7.68 mmol) in THF/water (3 mL/3 mL) was added benzyl chloroformate (482 mg, 2.82 
mmol) and the mixture was allowed to stir at RT for 16 h. The reaction was quenched with 3% HCl (20 
mL) and extracted with CH
2
Cl
2
 (3 x 20 mL), and the combined organic fractions were dried (MgSO
4
) 
and concentrated to give the title known compound 6 (676 mg, 2.56 mmol, 100%) as a colourless oil. 
Spectral data matched closely with that in the literature.
16
 [α]
D
20
 + 9.1 (c. 0.15 in CHCl
3
).
 1
H NMR: 
δ 7.38-7.22 (m, 5H, ArH); 5.75-5.58 (m, 1H, H4); 5.56 (d, J = 7.8 Hz, 1H, NH); 5.18-5.08 (m, 4H, 
ArCH
2
 and C5); 4.47 (dd, J = 6.3, 13.2 Hz, 1H, H2); 3.72 (s, 3H, OCH
3
); 2.54 (AB
q
, J = 6.3, 13.8 Hz, 
2H, H3). 
 
 
Methyl (2S,4E/Z)-2-(benzyloxycarboxamido)-7-(tert-butoxycarboxamido)-4-heptenoate (7) 
To a solution of 5 (220 mg, 1.29 mmol) in CH
2
Cl
2
 (13 mL) was added 6 (169 mg, 0.64 mmol) and 
RuCl
2
(PCy
3
)
2
(=CHPh) (53 mg, 0.064 mmol). The mixture was heated at reflux for 16 h before the 
solvent was removed by rotary evaporation and the crude product purified by flash column 
chromatography (silica gel, 6:1, hexane/EtOAc) to yield the title compound 7 (180 mg, 0.44 mmol, 
69%) as a brown oil. [α]
D
24
 - 34.6 (c. 0.3 in EtOH). υ
max
(neat) 2345, 2225, 1684, 1630 cm
-1
.
 1
H NMR: 
δ 7.36-7.28 (m, 5H, ArH); 5.52-5.34 (m, 3H, H4, H5, NH); 5.11/5.10 (s, 2H, H4’); 4.61 (bs, 1H, NH); 
4.49-3.90 (m, 1H, H2); 3.75/ 3,72 (s, 3H, OCH
3
); 3.18-3.04 (m, 2H, H7); 2.62-2.40 (m, 2H, H3); 2.26-
2.12 (m, 2H, H6); 1.43 (s, 9H, CH
3
).
 13
C NMR: δ 172.1/172.0, (C1); 155.8, (NCO
2
’); 155.6, (NCO
2
); 
131.8, (C4); 130.4, (C5); 129.3, (ArC1’); 128.6/128.4, (ArC2’ and ArC6’); 128.0/126.8, (ArC3’ and 
ArC5’); 126.0/125.3, (ArC4’); 79.0, (C(CH
3
)
3
); 66.9, (ArCH
2
); 53.6/53.4, (OCH
3
); 52.3/52.2, (C2); 
39.9/39.7, (C7); 35.5/35.2, (C3); 33.0/32.9, (C6); 28.3/28.1, (CH
3
). MS (ES, +ve) m/z 297 (100%), 407 
(20%) [MH
+
], 429 (90%) [MNa
+
]. HRMS (ES) calcd for C
21
H
31
N
2
O
6
 407.2182, found 407.2171. 
 
Methyl (2S,4E/Z)-2-(benzyloxycarboxamido)-7-(N,N’-di-tert-butoxycarbonyl-guanidino)-4-
heptenoate (8) 
To a solution of 7 (52 mg, 0.128 mmol) in CH
2
Cl
2
 (2 mL) was added TFA (2 mL) and the resulting 
solution was allowed to stir at RT for 3 h before being evaporated to dryness and resuspended in 
CH
2
Cl
2
 (2 mL) and triethylamine (0.2 mL). To this solution was added N1-tert-
butoxycarboxamido(trifluoromethylsulfonylimino) methyl propanamide (75 mg, 0.192 mmol) and the 
resulting mixture was allowed to stir overnight under a nitrogen atmosphere. The mixture was 
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concentrated and the crude product purified by flash column chromatography (silica gel, 5% MeOH/ 
CH
2
Cl
2
) to yield the title compound 8 (64 mg, 0.12 mmol, 93%) as a light brown/ red oil. [α]
D
23
 + 13.2 
(c. 0.05 in EtOH). υ
max
(neat) 2925, 2851, 2352, 2336, 1866, 1644, 1403 cm
-1
. 
 1
H NMR: δ 8.28 (bs, 1H, 
NH); 7.39-7.30 (m, 5H, ArH); 5.68-5.35 (m, 3H, H4, H5, NH); 5.09 (s, 2H, ArCH
2
); 4.49-4.39 (m, 1H, 
H2); 3.74/3.72 (s, 3H, OCH
3
); 3.49-3.35 (m, 2H, H7); 2.58-2.46 (m, 2H, H3); 1.89-1.82 (m, 2H, H6); 
1.48/1.47 (s, 9H, CH
3
). 
13
C NMR: δ 171.59, (C1); 163.4, (CN
3
); 156.0, (NCO’); 155.7, (NCO); 131.7, 
(C4); 130.1, (C5); 128.5, (ArC1’); 128.1, (ArC2’ and ArC6’); 126.6, (ArC3’ and ArC5’); 126.0, 
(ArC4’); 83.3, (C(CH
3
)
3
); 79.4, (C’(CH
3
)
3
); 67.0/66.9, (ArCH
2
); 53.4, (OCH
3
); 52.4/52.3, (C2); 
40.3/40.1, (C7); 35.3/34.5, (C3); 31.8/30.1, (C6); 28.2/28.0, (C(CH
3
)
3
); 26.9/26.8, (C(C’H
3
)
3
). MS (ES, 
+ve) m/z 549 (100%) [MH
+
]. HRMS (ES) calcd for C
27
H
41
N
4
O
8
 549.2924, found 549.2947. 
 
Methyl (2S)-2-amino-7-(tert-butoxycarboxamido)-heptanoate (9) 
To a solution of 7 (25 mg, 0.061 mmol) in THF (4 mL) was added palladium (10%) on activated 
carbon (13 mg, 0.006 mmol). The reaction vessel was evacuated, flushed with H
2
 and allowed to stir at 
RT for 16 h. The resulting crude product was filtered through celite and the solvent evaporated to yield 
the title compound 9 (15 mg, 0.055 mmol, 90 %) as a colourless oil. [α]
D
24
 + 9.6 (c. 0.1, in 
EtOH). υ
max
(neat) 2923, 2310, 2290, 1664, 1526 cm
-1
. 
 1
H NMR: δ 4.55 (bs, 1H, NH); 3.72 (s, 3H, 
OCH
3
); 3.44 (t, J = 6.0 Hz, 1H, H2); 3.10 (dd, J = 6.0, 12.6 Hz, 2H, H7); 1.80-1.68 (m, 4H, H3, H4); 
1.44 (s, 9H, CH
3
); 1.39-1.23 (m, 4H, H5, H6). 
13
C NMR: δ 176.5, (C1); 155.9, (NCO); 79.9, (C(CH
3
)
3
); 
54.2, (OCH
3
); 51.8, (C2); 40.3, (C7); 34.7, (C3); 29.9, (C6); 28.3, (CH
3
); 26.4, (C4); 25.3, (C5). MS 
(ES, +ve) m/z 219 (100%); 275 (90%) [MH
+
]. HRMS (ES) calcd for C
13
H
27
N
2
O
4
 275.1971, found 
275.1967. 
 
Methyl (2S)-2-amino-7-(N,N-di-tert-butoxycarbonyl-guanidino)-heptanoate (10) 
To a solution of 8 (50 mg, 0.091 mmol) in THF (10 mL) was added palladium (10%) on activated 
carbon (19 mg, 0.009 mmol) The reaction vessel was evacuated, flushed with H
2
 and the mixture 
allowed to stir at RT for 16 h. The resulting crude mixture was filtered through celite and the solvent 
was evaporated to yield the title compound 10 (28 mg, 0.091 mmol, 100 %) as a red oil. [α]
D
28
 - 15.3 (c. 
0.25, in EtOH). υ
max
(neat) 2934, 2360, 2338, 1746, 1722, 1633, 1371, 1155 cm
-1
. 
 1
H NMR: δ 8.34 (bs, 
1H, NH); 3.79-3.76 (m, 1H, H2); 3.74 (s, 3H, OCH
3
); 3.40 (t, J = 6.6 Hz, 2H, H7); 1.92-1.82 (m, 4H, 
H3 and H4); 1.50 (s, 18H, 6 x CH
3
); 1.42-1.35 (m, 4H, H5 and H6). 
13
C NMR: δ 171.6, (C1); 163.4, 
(CN
3
); 156.1/153.3, (NCO); 83.1/79.3, (C(CH
3
)
3
); 54.2, (OCH
3
); 52.1, (C2); 40.7, (C7); 35.3/34.5, (C3); 
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28.6/28.2, (CH
3
); 28.0, (CH
3
) 26.8/26.6, (C4); 26.1/26.0, (C5). MS (ES, +ve) m/z 417 (100%) [MH
+
]. 
HRMS (ES) calcd for C
19
H
37
N
4
O
6
 417.2713, found 417.2710. 
 
(2S)-2,7-Diaminoheptanoic acid dihydrochloride (1) 
A solution of 9 (16 mg, 0.058 mmol) in 10M HCl (3 mL) was allowed to stir at RT for 48 h before 
evaporation of the solvent and drying of the residue (P
2
O
5
) to yield the title compound 1 (14 mg, 0.058 
mmol, 100%) as a hygroscopic white solid. [α]
D
22
 + 10.9 (c. 0.1 in 2M HCl) (Lit.
11
 [α]
D
23
 +14.4, and 
Lit.
12
 [α]
D
23
 -10.6 for the opposite (R)-enantiomer). υ
max
(neat) 2927, 2870, 2851, 1734, 1559, 1541, 
1457, 1103 cm
-1
. 
1
H NMR (D
2
O): δ 3.90 (t, J = 6.3 Hz, 1H, H2); 2.83 (t, J = 7.5 Hz, 2H, H7); 1.80-1.70 
(m, 2H, H3); 1.58-1.48 (m, 2H, H5); 1.32-1.22 (m, 4H, H6 and H4). 
13
C NMR (D
2
O, 125 MHz): 
δ 172.5, (C1); 53.1, (C2); 39.4, (C7); 29.6, (C3); 26.5, (C6); 25.3, (C4); 23.8, (C5). MS (ES, +ve) m/z 
161 (100%) [MH
+
]. HRMS (ES) calcd for C
7
H
17
N
2
O
2
 161.1290, found 161.1294. 
 
(2S)-2-Amino-7-guanidinoheptanoic acid dihydrochloride (2) 
A solution of 10 (34 mg, 0.082 mmol) in 10M HCl (5 mL) was allowed to stir at RT for 48 h before 
evaporation of the solvent and drying of the residue (P
2
O
5
) to yield the title compound 2 (23 mg, 0.082 
mmol, 100%) as a hygroscopic white solid. [α]
D
20
 – 23.3 (c. 0.03 in HCl). υ
max
(neat) 2927, 2852, 1752, 
1617, 1552, 1140 cm
-1
. 
1
H NMR (D
2
O): δ 3.77 (t, J = 6.3 H Hz, 1H, H2); 3.14 (t, J = 6.6 Hz, 2H, H7); 
1.90-1.78 (m, 2H, H3); 1.64-1.52 (m, 2H, H5); 1.46-1.30 (m, 4H, H6 and H4).
 13
C NMR (D
2
O): δ 172.6, 
(C1); 53.1, (C2); 41.1, (C7); 29.8, (C3); 27.6, (C6); 25.5, (C4); 23.9, (C5). MS (ES, +ve) m/z 203 
(100%) [MH
+
]. HRMS (ES) calcd for C
8
H
19
N
4
O
2
 203.1508, found 203.1500. 
 
Methyl (2S,5S)-5-(4-allyloxybenzyl)-3,6-diaza-2-(5-[tert-butoxycarboxamido]pentyl)-4,7-
dioxooctanoate (12) 
To a solution of O-allyl-N-acetyl-(S)-tyrosine 11
21
 (53 mg, 0.20 mmol) and 9 (65 mg, 0.24 mmol) in 
CH
3
CN (10 mL), was added EDCI (38 mg, 0.20 mmol) and HOBt (30 mg, 0.22 mmol) and the 
resulting mixture was allowed to stir at RT for 16 h. The reaction was diluted with H
2
O (20 mL) and 
the solid precipitate collected by vacuum filtration, then dissolved in EtOAc (30 mL) and the EtOAc 
solution was washed with water (3 x 30 mL). The crude product was purified by column 
chromatography (silica gel, 5% MeOH/CH
2
Cl
2
) to afford 12 (103 mg, 0.20 mmol, 100%) as an off-
white solid. Mp 96-103
o
C. υ
max
(neat) 2943, 2942, 1832, 1618,1604 1565, 1411, 1132 cm
-1
.
 1
H NMR: 
δ 7.11 (d, J = 8.7 Hz, 2H, ArH2” and ArH6”); 6.82 (d, J = 8.7 Hz, 2H, ArH3” and ArH5”); 6.50 (d, J = 
 
10 
7.8 Hz, 1H, NH); 6.03 (m, 1H, H2”’); 5.39 (dd, J = 1.8, 17.4 Hz, 1H, H3
a
”’); 5.26 (dd, J = 1.8, 9.3 Hz, 
1H, H3
b
”’); 4.66 (m, 2H, H2 and H5); 4.48 (m, 2H, H1”’); 3.69 (s, 3H, OCH
3
); 2.98 (m, 4H, H5’ and 
ArCH
2
); 1.96 (s, 3H, H8); 1.75 (m, 2H, H1’); 1.64 (m, 2H, H3’); 1.43 (s, 9H, C(CH
3
)
3
); 1.26 (m, 4H, 
H2’ and H4’).
 13
C NMR: δ 172.2, C4; 171.2, C1; 170.2, C7; 157.5, NCO
2
; 156.2, ArC4”; 133.2, C2”; 
130.2, ArCH2” and ArCH6; 128.6, ArC1”; 117.5, C3”’; 114.7, ArCH3” and ArCH5”; 79.0, C(CH
3
)
3
; 
68.7, C1”’; 54.5, C2; 54.4, C5; 52.2, C5’; 52.1, OCH
3
; 40.0, C4’; 37.2, ArCH
2
; 31.8, C1’; 28.3, 
C(CH
3
)
3
; 26.2, C8; 25.9, C3’; 22.9, C2’. Mass Spectrum (ES, +ve) m/z 520 (100%) [MH
+
]. HRMS 
calcd for C
27
H
41
N
3
O
7
 542.2842, found 542.2855. 
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